We are live on
!
Find out more
DP
Diadema Partners Portfolio holdings
AUM
$588M
1-Year Est. Return
182.75%
This Fund
S&P 500
This Quarter
Est. Return
-0.18%
1 Year Est. Return
+182.75%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$383M
AUM Growth
+$150M
(+64%)
Cap. Flow
+$155M
Cap. Flow
% of AUM
40.41%
Top 10 Holdings %
Top 10 Hldgs %
48.06%
Holding
163
New
56
Increased
35
Reduced
10
Closed
61
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$20.5M |
| 2 |
Eli Lilly
LLY
|
+$16.1M |
| 3 |
Jazz Pharmaceuticals
JAZZ
|
+$9.45M |
| 4 |
Neurocrine Biosciences
NBIX
|
+$7.89M |
| 5 |
argenx
ARGX
|
+$7.32M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$9.05M |
| 2 |
AbbVie
ABBV
|
+$8.88M |
| 3 |
Teva Pharmaceuticals
TEVA
|
+$6.68M |
| 4 |
BPMC
Blueprint Medicines
BPMC
|
+$5.6M |
| 5 |
AstraZeneca
AZN
|
+$3.93M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 32.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
CALL
Amgen
AMGN
$208B
| $32.2M | 8.4% |
+103,300
| New | +$30.5M |
|
2
CALL
Pfizer
PFE
$143B
| $22.8M | 5.95% |
+900,000
| New | +$23.6M |
|
|
3
Regeneron Pharmaceuticals
REGN
$78.5B
| $18.9M | 4.94% |
+29,828
| New | +$20.5M |
|
4
PUT
Corcept Therapeutics
CORT
$12.4B
| $17.2M | 4.48% |
+150,200
| New | +$9.14M |
|
|
5
PUT
Eli Lilly
LLY
$1.02T
| $17.1M | 4.46% |
+20,700
| New | +$17.2M |
|
|
6
PUT
Amgen
AMGN
$208B
| $16.2M | 4.24% |
+52,100
| New | +$15.4M |
|
|
7
Eli Lilly
LLY
$1.02T
| $15.9M | 4.16% |
+19,302
| New | +$16.1M |
|
|
SLNO
8
CALL
DELISTED
Soleno Therapeutics
SLNO
| $15.7M | 4.09% |
219,400
+124,800
| +132% | +$6.08M |
|
|
SLNO
9
PUT
DELISTED
Soleno Therapeutics
SLNO
| $15.5M | 4.05% |
217,000
+41,600
| +24% | +$2.03M |
|
|
10
PUT
Regeneron Pharmaceuticals
REGN
$78.5B
| $12.7M | 3.31% |
+20,000
| New | +$13.8M |
|
|
11
Jazz Pharmaceuticals
JAZZ
$15.9B
| $10.8M | 2.82% |
87,189
+72,470
| +492% | +$9.45M |
|
|
12
CALL
Jazz Pharmaceuticals
JAZZ
$15.9B
| $8.79M | 2.29% |
+70,800
| New | +$9.24M |
|
|
NVO
13
PUT
Novo Nordisk
NVO
$208B
| $8.65M | 2.26% |
+124,600
| New | +$10.3M |
|
|
14
CALL
Eli Lilly
LLY
$1.02T
| $8.26M | 2.15% |
+10,000
| New | +$8.32M |
|
15
TG Therapeutics
TGTX
$7.96B
| $8.2M | 2.14% |
207,883
+160,078
| +335% | +$5.39M |
|
|
NVO
16
CALL
Novo Nordisk
NVO
$208B
| $7.55M | 1.97% |
+108,700
| New | +$8.98M |
|
|
17
argenx
ARGX
$54.6B
| $7.18M | 1.87% |
12,279
+11,600
| +1,708% | +$7.32M |
|
|
18
Neurocrine Biosciences
NBIX
$16.8B
| $6.88M | 1.8% |
+62,247
| New | +$7.89M |
|
|
SLNO
19
DELISTED
Soleno Therapeutics
SLNO
| $6.64M | 1.73% |
93,002
+21,014
| +29% | +$1.02M |
|
20
PUT
Alnylam Pharmaceuticals
ALNY
$27.5B
| $5.4M | 1.41% |
+20,000
| New | +$5.14M |
|
21
CALL
Apogee Therapeutics
APGE
$10.1B
| $4.72M | 1.23% |
+126,300
| New | +$4.88M |
|
|
22
CALL
Corcept Therapeutics
CORT
$12.4B
| $4.57M | 1.19% |
+40,000
| New | +$2.43M |
|
23
CALL
BridgeBio Pharma
BBIO
$15.7B
| $4.54M | 1.19% |
131,400
+31,400
| +31% | +$1.06M |
|
24
PUT
Ultragenyx Pharmaceutical
RARE
$2.45B
| $4.46M | 1.16% |
123,300
+17,800
| +17% | +$741K |
|
|
25
CALL
Ultragenyx Pharmaceutical
RARE
$2.45B
| $4.24M | 1.11% |
117,000
+64,700
| +124% | +$2.69M |
|
Similar funds
MC
PFG
FMI
EGWAG
PFG
GIM
FL
BA
Diadema Partners's Q1 2025 Portfolio in Review
As of Q1 2025, Diadema Partners held 163 positions worth $383M, up 64% from $233M the previous quarter. Its ten largest holdings account for 48% of the portfolio.
Diadema Partners deployed $155M of net new capital in Q1 2025, opening 56 new positions and adding to 35 existing holdings. Its largest new stake was Regeneron Pharmaceuticals: 29,828 shares worth $18.9M.
By sector, the portfolio is most concentrated in Healthcare at 33% of assets, down from 38% a quarter earlier.
On the sell side, the largest reduction was Ascendis Pharma A/S, an estimated $2.42M trimmed.
- Diadema Partners's largest Q1 2025 buy was Regeneron Pharmaceuticals: 29,828 shares worth $18.9M.
- Diadema Partners added most to Jazz Pharmaceuticals in Q1 2025, an estimated $9.45M increase.
- Diadema Partners's biggest Q1 2025 reduction was Ascendis Pharma A/S, cutting an estimated $2.42M.
- Diadema Partners fully exited Bristol-Myers Squibb in Q1 2025, selling an estimated $9.05M.
- Diadema Partners's ten largest holdings make up 48% of its $383M portfolio in Q1 2025.
- Diadema Partners opened 56 new positions and closed 61 in Q1 2025.
- Diadema Partners's portfolio value rose 64% quarter-over-quarter to $383M.
Based on Diadema Partners's 13F filing for Q1 2025, filed 15 May 2025.